Revisor Wealth Management LLC Purchases 9,044 Shares of Medtronic PLC $MDT

Revisor Wealth Management LLC grew its stake in shares of Medtronic PLC (NYSE:MDT) by 70.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 21,939 shares of the medical technology company’s stock after acquiring an additional 9,044 shares during the quarter. Revisor Wealth Management LLC’s holdings in Medtronic were worth $2,173,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of MDT. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Medtronic by 8.7% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 757,679 shares of the medical technology company’s stock worth $72,783,000 after buying an additional 60,930 shares in the last quarter. Belpointe Asset Management LLC increased its holdings in Medtronic by 57.3% in the 4th quarter. Belpointe Asset Management LLC now owns 16,712 shares of the medical technology company’s stock worth $1,605,000 after purchasing an additional 6,088 shares in the last quarter. Fortis Capital Advisors LLC increased its holdings in Medtronic by 112.3% in the 4th quarter. Fortis Capital Advisors LLC now owns 4,667 shares of the medical technology company’s stock worth $448,000 after purchasing an additional 2,469 shares in the last quarter. Krilogy Financial LLC grew its position in shares of Medtronic by 2.7% in the 4th quarter. Krilogy Financial LLC now owns 18,730 shares of the medical technology company’s stock valued at $1,886,000 after buying an additional 489 shares during the last quarter. Finally, Benedict Financial Advisors Inc. boosted its holdings in Medtronic by 0.4% in the fourth quarter. Benedict Financial Advisors Inc. now owns 75,957 shares of the medical technology company’s stock valued at $7,296,000 after acquiring an additional 283 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

MDT has been the topic of several analyst reports. Sanford C. Bernstein upped their target price on Medtronic from $111.00 to $112.00 and gave the company an “outperform” rating in a research report on Friday, January 9th. JPMorgan Chase & Co. cut their price target on Medtronic from $105.00 to $100.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. Stifel Nicolaus dropped their target price on Medtronic from $105.00 to $95.00 and set a “hold” rating on the stock in a report on Monday, April 6th. CICC Research initiated coverage on Medtronic in a research report on Friday, January 30th. They set an “outperform” rating for the company. Finally, Daiwa Securities Group decreased their price target on Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, February 27th. Sixteen equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Medtronic currently has an average rating of “Moderate Buy” and an average price target of $109.25.

Medtronic Price Performance

NYSE:MDT opened at $86.24 on Monday. The firm has a market capitalization of $110.72 billion, a price-to-earnings ratio of 24.02, a P/E/G ratio of 2.24 and a beta of 0.75. Medtronic PLC has a 52-week low of $79.93 and a 52-week high of $106.33. The stock has a fifty day moving average of $91.51 and a 200 day moving average of $95.71. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the company earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were paid a dividend of $0.71 per share. The ex-dividend date of this dividend was Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.3%. Medtronic’s payout ratio is 79.11%.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares of the company’s stock, valued at $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.26% of the stock is currently owned by company insiders.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).